- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03294473
Centralized Reminder Recall - Flu RCT2
Centralized IIS-Based Reminder Recall to Increase Influenza Vaccination Rates in New York State - Second Trial in New York State
This study is related to a previous study, Clinicaltrials.gov ID: NCT02924467. There are some modifications in relation to the intervention arms as well as the use of a different cohort, thereby justifying the second submission to Clinicaltrials.gov. This trial is taking place in New York State, through partnership with the New York State Health Department (excluding New York City), and Colorado. Each state will have it's own Clinicaltrial.gov submission -- this was decided as some of the intervention components are different enough that separate registrations were warranted.
Despite U.S. guidelines for influenza vaccination of all children starting at 6 months, only about half of children are vaccinated annually leading to substantial influenza disease in children and spread of disease to adults. A major barrier is that families are not reminded about the need for their children to receive influenza vaccination. The investigators will evaluate the impact of patient reminder/recall (R/R) performed by state immunization information systems to improve influenza vaccination rates by using 4 clinical trials (2 per state) in two different states. The investigators will assess effectiveness and cost-effectiveness of 1) autodialer R/R 2) text messages R/R 3) mailed postcard R/R as compared to 4) standard of care control (no R/R).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Annual epidemics of influenza A and B cause substantial morbidity and mortality in the US with high rates of hospitalizations, emergency department visits, outpatient visits, and medical costs. Epidemics cause up to 40,000 deaths/year (mostly elderly) and extensive morbidity among children who play a key role in instigating and expanding epidemics. In addition, concerns about pandemic influenza heighten the importance of new mechanisms to rapidly inform the population about influenza and direct efforts for rapid vaccine delivery.
Since 2010, the Advisory Committee on Immunization Practices (ACIP) has recommended influenza vaccination for all children >6 months of age. However, vaccination rates remain very low. For the 2012-2013 season, only 56% of children 2-17years were vaccinated. Modeling studies suggest that as many as 19 million cases of influenza could be prevented if child vaccination rates were raised to 70% nationally.
The most effective strategy recommended by CDC and the Task Force on Community Preventive Services for improving childhood influenza vaccination rates is reminder/recall (R/R), sent by phone or mail, notifying parents of the need to vaccinate their child. We and others have shown that R/R can improve influenza vaccination rates by up to 20%. However, <16% of practices use R/R; barriers are practice costs, insufficient staff time and expertise, and lack of predictability regarding receipt of vaccine supplies.
Statewide immunization information systems (IISs) now exist in all states to track childhood vaccinations, but they have not been used for influenza vaccine R/R because of lack of evidence for their effectiveness and a lack of a template for IIS-based R/R. The investigators have united two leading immunization research groups (Denver, CO and Rochester (lead by personnel at UCLA), NY) to assess the impact of centralized IIS-based influenza vaccine R/R and to evaluate the effect of three types of R/R (autodialer, text message and mail R/R) over usual care. The investigators will also develop tools to aid other states in creating efficient IIS R/R systems for seasonal and possible pandemic influenza outbreaks.
For this second R/R trial in New York State, the intent is to evaluate the impact of reminder recalls, in the form of 1) autodialers 2) text messages and 3) postcards versus the standard of care control group, specifically in relation to raising influenza vaccination rates among children 6m-17 years of age.
The proposed design of this 4-arm RCT:
- standard of care control
- autodialer R/R -- with brief educational messages, practice name and practice phone number
- text message R/R-- with brief educational messages, practice name and practice phone number
- mailed (postcards) R/R-- with brief educational messages, practice name and practice phone number
Hypothesis 1: All IIS-C R/R modalities will be more effective than usual care
Hypothesis 2: Text messaging will be more cost-effective than other modalities
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90095
- University of California, Los Angeles
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- a record in the New York State Immunization Information System
- in need of at least one influenza vaccination at the time of the beginning of the study
- affiliated with a participating practice (145 randomly selected)
Exclusion Criteria:
- no record within the New York State Immunization Information System
- up to date on their influenza vaccination
- not affiliated with an eligible practice
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Autodial R/R
R/R Autodialers:Participants in this group will receive up to 3 influenza vaccination reminders via telephone call - with a brief educational message + practice name + practice phone number
|
Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
|
Eksperimentell: Text Message R/R
R/R Texting: Participants in this group will receive up to 3 influenza vaccination reminders via text message - with a brief educational message + practice name + practice phone number
|
Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
|
Eksperimentell: Postcard R/R
R/R Mailed Postcard:Participants in this group will receive up to 3 influenza vaccination reminders via postcard - with a brief educational message + practice name + practice phone number
|
Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
|
Ingen inngripen: Standard of Care Control
Participants in this group will not receive any influenza vaccination reminders
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The primary outcome is receipt of influenza vaccine comparing effectiveness of standard of care control to autodialer, text message and postcard R/R
Tidsramme: 6 months
|
Based on our prior studies, we plan to send up to 3 autodialer, text messages or postcards (based on randomization) reminders, roughly every 5-6 weeks.
This will begin in October 2017 and end in December 2017.
Outcomes are assessed at 6 months using IIS data.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Cost of the R/R intervention
Tidsramme: 6 months
|
A cost-effectiveness analysis will be conducted to determine which modality of R/R (autodialer, text message or mailed postcard) is the most cost-effective in relation to improving influenza vaccination rates.
The cost analysis will also compare autodialer to text, autodialer to postcard, and texting to postcards.
|
6 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Peter Szilagyi, MD, MPH, University of California, Los Angeles
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 17-001153 (Annen identifikator: University of California, Los Angeles, IRB)
- 1R01AI114903 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på RNA-virusinfeksjoner
-
Centre for Infectious Disease Research in ZambiaUniversity of OxfordFullførtHepatitt B-virus | Health Care Associated InfectionZambia
-
TakedaFullførtFlavivirus infeksjoner | Friske deltakere | Virus, Zika | Zika virus sykdomForente stater, Puerto Rico
-
Emergent BioSolutionsFullførtZika-virusinfeksjon | Zika virus sykdomCanada
-
U.S. Army Medical Research and Development CommandAktiv, ikke rekrutterende
-
Institute of Tropical Medicine, BelgiumFullførtOverføring | Zika-virus | Zika virus sykdom | VirusutløsningBelgia
-
University Hospital, ToulouseInstitut Pasteur; Centre Hospitalier Universitaire de Pointe-a-PitreFullført
-
Valneva Austria GmbHEmergent BioSolutionsFullførtZika-virusinfeksjon | Zika-virusForente stater
-
National Institute of Allergy and Infectious Diseases...FullførtInfluensa A-virus, H5N1-subtype | Influensa A-virus | Influensavirus A | Orthomyxoviridae | H5N1 virusForente stater
-
National Institute of Allergy and Infectious Diseases...FullførtEbola-virusForente stater, Kongo, Den demokratiske republikken
-
ChimerixTilbaketrukket
Kliniske studier på R/R - Autodialers
-
Klinikum NürnbergUkjent
-
University of California, Los AngelesNational Institute of Allergy and Infectious Diseases (NIAID)FullførtLuftveisinfeksjoner | Influensa | VaksinerForente stater
-
Daping Hospital and the Research Institute of Surgery...Har ikke rekruttert ennå
-
LifeScanFullført
-
University of Colorado, DenverAgency for Healthcare Research and Quality (AHRQ)FullførtVaksinasjonsraterForente stater
-
Taiyuan LiFullførtEndetarmskreft | Robotkirurgi | Naturlig åpning prøveekstraksjonskirurgiKina
-
University of California, Los AngelesNational Institute of Allergy and Infectious Diseases (NIAID)Fullført
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Rekruttering
-
University of British ColumbiaStanford UniversityFullført